MGRX Mangoceuticals, Inc.
Mergers ·
Two strategic investors paid the first $1.75 million tranche for a 17.5% interest in MangoRx IP, a former subsidiary of Mangoceuticals. The other $750,000, for 7.5%, is due by November 28, 2026, and the company's cash had fallen to $228,688 by June 30.
Five accredited investors bought restricted stock under subscription agreements signed August 26, 2025 and August 29, 2025. No underwriters were used.
Mangoceuticals, Inc. connects consumers to licensed healthcare professionals through its website, MangoRX.com, for care via telehealth on its customer portal. It focuses on developing, marketing and selling men's wellness products and services through a telemedicine platform, particularly in erectile dysfunction, hair loss, testosterone replacement or enhancement therapies and weight management. The company is commercially marketing compounded products under the brand names Mango for erectile dysfunction, Grow for hair loss, Mojo for hormone balance and therapy, and Slim for weight loss. The compounded products are produced and fulfilled by Epiq Scripts, LLC, a related party compounding pharmacy that is 52% owned by Jacob Cohen, the company's Chief Executive Officer and Chairman. The compounded products are available to patients when a prescribing physician determines the compounded drug is necessary for the individual patient. The company also uses Epiq Scripts to fulfill all patient orders of its Prime product.
| Product or program | What it is | Stage |
|---|---|---|
| Mango | Compounded erectile dysfunction product | commercially marketed |
| Grow | Compounded hair loss product | commercially marketed |
| Mojo | Compounded hormone balance and therapy product | commercially marketed |
| Slim | Compounded weight loss product | commercially marketed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $456,021 | $615,873 |
| Net income (loss) | -$20.6 million | -$8.7 million |
| Cash from operations | -$5.9 million | -$4.9 million |
| Cash and equivalents | $1.5 million | $58,653 |
Our latest story on this, dated Sep 2, 2025: "Mangoceuticals sells 709,677 shares at $1.55 in $1,100,000 private placement". The story links the filing or release it is based on. Read the story.
Mangoceuticals, Inc. trades under the ticker MGRX on NASDAQ.
Mangoceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Mangoceuticals, Inc. is 1938046. Its filings are on SEC EDGAR.
21,567,422 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Mangoceuticals, Inc. under United States.
Our directory classifies Mangoceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Mangoceuticals, Inc. is US56270V2051.
aibio.space lists Mangoceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as TX.
Mangoceuticals, Inc. connects consumers to licensed healthcare professionals through its website, MangoRX.com, for care via telehealth on its customer portal. It focuses on developing, marketing and selling men's wellness products and services through a telemedicine platform, particularly in erectile dysfunction, hair loss, testosterone replacement or enhancement therapies and weight management.
Mango: Compounded erectile dysfunction product Stage: commercially marketed.
Grow: Compounded hair loss product Stage: commercially marketed.
$456,021 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Mangoceuticals, Inc. reported a net loss of $20.6 million for the fiscal year ended Dec 31, 2025, and used $5.9 million of cash in operations, per its annual report to the SEC.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,7.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,5.02,5.03,7.01,9.01). Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,5.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 3.02,3.03,5.02,5.03,5.07,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.01,5.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio